Antiviral methods and compounds
AssigneeImmugen Pharmaceuticals, Inc.
InventorCraig R. Travis
Life of this patent
Estimating the term…
Abstract
The invention provides a method, compounds, and compositions for inhibiting the replication or proliferation of a virus. In accordance with the invention, at least one cannabichromene derivative is exposed to the virus, a host cell, or an infected cell under conditions sufficient to inhibit the replication or proliferation of the virus.
Claims14
A cannabichromene derivative having following formula:
- 9
- wherein:
- R1 is:
- a) H,
- b) a C1-4 alkyl group or ester thereof,
- c) COOH,
- d) OH,
- e) a O—C1-5 alkyl (preferably OCH3) or alkanoyl, optionally substituted by mono- or di-methylamino or ethylamino groups,
- f) a O—CO—C3-10 alkyl group containing a carboxyl or amino group, g)
- 10
- h) a p-aminobenzyl group or a C1-7 aminoalkyl group or an organic or mineral acid addition salt thereof, an isocyanate or isothiocyanate derivative of the p-aminobenzyl or aminoalkyl group, a carboxyl terminated derivative of the aminoalkyl group having from 1 to 7 additional carbon atoms or a salt thereof, and an activated derivative of the carboxyl terminated derivative;
- i) R1 and R2 comprise a substituent of the formula —O(CH2)3-5, wherein R1 and R2, together with the carbon atoms to which they are bonded, comprises a ring where at least one hydrogen atom thereof is optionally substituted with a halogen (e.g., fluorine, bromine, iodine, astatine);
- j) a lactone (e.g., COCOH);
- or
- k) CH(CH3)CO2H or —OCOCH3
- R2 is:
- a) H, OH, COOH, or a halogen
- b) C1-6 carboxy or alkoxy group, or
- c) R1 and R2 comprise a substituent of the formula —O(CH2)3-5, wherein R1 and R2, together with the carbon atoms to which they are bonded, comprises a ring where at least one hydrogen atom thereof is optionally substituted with a halogen.
- R3 is:
- a) (W)m-Y-(Z)n, wherein
- W is a C5-12 straight or branched (preferably 1′SCH3-5, 2R′CH3 dimethyl) alkyl (e.g., -pentyl, -hexyl, -heptyl, -octyl, or -nonyl), alkenyl, alkynyl, group, or mixture thereof, optionally substituted with at least one halogen (e.g., halogen terminal group or even dihalogen),
- Y is a bond, O, S, SO, SO2, CO, NH, N(C1-6 alkyl), or NCS,
- Z is:
- i) a C5-12 alkyl, alkenyl, alkynyl, group, or mixture thereof, optionally substituted with at least one halogen, optionally substituted with a terminal aromatic ring,
- ii) CN1-3, CO2H, or CO2C1-4 alkyl, CONH2, CONHC1-4 alkyl, or CON(C1-4 alkyl)2, wherein each C1-4 alkyl on the amide nitrogen can be the same or different, or
- iii) a phenyl or benzyl group, optionally substituted with halo, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, CN, CF3, CO2H, or CO2C1-4 alkyl, CONH2, CONHC1-4 alkyl, or CON(C1-4 alkyl)2, wherein each C1-4 alkyl on the amide nitrogen can be the same or different, and wherein
- m and n are the same or different, and each is either 0 or 1,
- b) a C5-12 alkyl or haloalkyl group, optionally substituted with a terminal aromatic ring, CN1-3, NCS, CO2H, or CO2C1-4 alkyl, CONH2, CONHC1-4 alkyl, or CON(C1-4 alkyl)2, wherein each C1-4 alkyl on the amide nitrogen can be the same or different, or
- c) a C5-12 alkene or alkyne group, optionally substituted with a halogen, dithiolene, terminal aromatic ring, CN1-3, NCS, CO2H, or CO2C1-4 alkyl, CONH2, CONHC1-4 alkyl, or CON(C1-4 alkyl)2, wherein each C1-4 alkyl on the amide nitrogen can be the same or different;
- R6 is selected from the group consisting of:
- a) hydrogen,
- b) hydroxy or lactone,
- c) halo,
- d) C1-6 alkoxy, C1-6 alkylthio, C1-6 alkyl, or C1-6 haloalkyl,
- e) CN,
- f) N3,
- g) CO2H,
- h) CO2—C1-4 alkyl,
- i) C(Y)(Z)-OH,
- j) C(Y)(Z)-O—C1-4 alkyl, and
- k) C1-6 alkyl-CO2—Y,
- wherein Y and Z are each independently H or C1-6 alkyl,
- R7 is selected from the group consisting of:
- a) hydrogen,
- b) hydroxy or lactone,
- c) halo, d) C hd 1-6 alkoxy, C1-6 alkylthio, C1-6 alkyl, or C1-6 haloalkyl,
- e) CN,
- f)N3,
- g) CO2H,
- h) CO2—C1-4 alkyl,
- i) C(Y)(Z)-OH,
- j) C(Y)(Z)-O—C1-4 alkyl,
- k) C1-6 alkyl-CO2—Y, and
- l) =O or =S;
- wherein Y and Z are each independently H or C1-6 alkyl,
- R12 and R12′ together form =O or =S, or each is independently selected from the group consisting of:
- a) hydrogen,
- b) hydroxy or lactone,
- c) halo,
- b) C1-6 alkoxy, C1-6 alkylthio, C1-6 alkyl, or C1-6 haloalkyl,
- c) CN,
- d) N3,
- d) CO2H,
- e) CO2—C1-4 alkyl,
- f) C(Y)(Z)-OH,
- g) C(Y)(Z)-O—C1-4 alkyl, and
- h) C1-6 alkyl-CO2—Y,
- wherein Y and Z are each independently H or C1-6 alkyl;
- and
- Q is:
- a) O or S, or
- b) N-W, wherein W is:
- i) hydrogen,
- ii) C1-6 alkoxyalkyl, C1-6 alkyl, or C1-6 haloalkyl
- iii) OC1-6 alkyl, or OC1-6 haloalkyl,
- iv) CN,
- v) C1-6 alkyl,
- vi) C(Y)(Z)C1-4 alkyl, or
- vii) C1-6 alkyl-CO2-Z,
- wherein Y and Z are each independently H or C1-6 alkyl.
An antiviral composition comprising the cannabichromene derivative of claim 15 and an agriculturally-acceptable carrier.
A pharmaceutical composition comprising the cannabichromene derivative of claim 15 and a pharmacologically-acceptable carrier.
Dependencies are inferred from the claim text.